| Bioactivity | Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is used for the study of Parkinson's disease[1][2]. |
| Invitro | IRL752 fumarate displays its highest in vitro affinities for 5-HT and NA-related targets[2]. |
| In Vivo | IRL752 (3.7-100 µmol/kg, s.c.) fumarate has no significant effect on acute hyper-dopaminergic or hypo-glutamatergic motor responses, but reverses deficits resulting from hypomonoaminergic function[2]. Animal Model: |
| Name | Pirepemat fumarate |
| CAS | 2251806-70-7 |
| Formula | C15H17F2NO5 |
| Molar Mass | 329.30 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson's Disease. [2]. S Hjorth, et al. (3 S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752) -a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent. J Pharmacol Exp Ther. 2020 Sep;374(3):404-419. |
Pirepemat fumarate
CAS: 2251806-70-7 F: C15H17F2NO5 W: 329.30
Pirepemat (IRL752) fumarate is a corticalpreferring catecholamine- and cognition-promoting agent. Pirepemat fumarate is
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.